Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥2,209 JPY
Change Today -6.00 / -0.27%
Volume 982.2K
As of 1:00 AM 11/25/15 All times are local (Market data is delayed by at least 15 minutes).

mitsubishi tanabe pharma (4508) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/10/15 - ¥2,442
52 Week Low
01/7/15 - ¥1,701
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MITSUBISHI TANABE PHARMA (4508)

Related News

No related news articles were found.

mitsubishi tanabe pharma (4508) Related Businessweek News

No Related Businessweek News Found

mitsubishi tanabe pharma (4508) Details

Mitsubishi Tanabe Pharma Corporation manufactures and sells pharmaceuticals in Japan and internationally. The company offers autoimmune drugs, including Remicade agent for rheumatoid arthritis and Crohn’s disease, Bechet’s disease with refractory uveoretinitis, psoriasis, ankylosing spondylitis, and ulcerative colitis; and Simponi agent for rheumatoid arthritis. It also provides drugs for diabetes and kidney diseases, such as Kremezin agent for chronic renal failure; and Tanatril agent for hypertension and diabetic nephropathy with type I diabetes mellitus, etc. In addition, the company offers drugs for central nervous system diseases comprising Radicut, a cerebral neuroprotectant; Ceredist agent for spinocerebellar degeneration; Depas, an anti-anxiety agent; and Lexapro, an anti-depressant agent. Further, it provides Maintate agent for treatment of hypertension, angina pectoris, ventricular extrasystole, chronic heart failure, and atrial fibrillation; Talion agent for allergic disorders; Urso agent for the improvement of hepatic, biliary, and digestive function; Anplag, an anti-platelet agent; and Herbesser, an agent for angina pectoris and hypertension. Additionally, the company offers vaccines, such as TETRABIK, a combined vaccine for diphtheria, pertussis, tetanus, and poliomyelitis; and influenza. It also provides over-the-counter products, including herbal and digestive medicines, as well as oral solutions for tonic and nutritional supplement; oral agent for allergic rhinitis; and products for the treatment of skin conditions and recurrent vaginal candidiasis. The company also offers pharmaceutical information and real estate management services; sells generic pharmaceuticals, chemicals, etc.; invests in bio-ventures; and is involved in distribution and warehouse operations. The company was founded in 1678 and is headquartered in Osaka, Japan. Mitsubishi Tanabe Pharma Corporation is a subsidiary of Mitsubishi Chemical Holdings Corporation.

8,457 Employees
Last Reported Date: 06/19/15
Founded in 1678

mitsubishi tanabe pharma (4508) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

mitsubishi tanabe pharma (4508) Key Developments

Mitsubishi Tanabe Pharma Corporation Declares Second Quarter Dividend Payable from December 1, 2015; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2016

Mitsubishi Tanabe Pharma Corporation declared dividend of ¥22 per share for the second quarter of Fiscal year 2015. Planned date of start of dividend payments is December 1, 2015. The company paid ¥20 per share for the second quarter of Fiscal year 2014. The company expects year end dividend of ¥22 per share for the fiscal year ending March 31, 2016. Total dividend for the fiscal year 2016 is ¥44 compared to ¥42 for the fiscal year 2014.

Mitsubishi Tanabe Pharma Corporation Reports Consolidated Earnings Results for the Six Months Ended September 30, 2015; Provides Earnings Guidance for the Year Ending March 31, 2016

Mitsubishi Tanabe Pharma Corporation reported consolidated earnings results for the six months ended September 30, 2015. For the period, the company reported net sales of JPY 201,729 million against JPY 198,883 million a year ago. Operating income was JPY 43,519 million against JPY 34,954 million a year ago. Ordinary income was JPY 43,318 million against JPY 35,455 million a year ago. Income before income taxes and non-controlling interests was JPY 43,123 million against JPY 46,356 million a year ago. Net income attributable to shareholders of the company was JPY 29,148 million against JPY 32,518 million a year ago. Net cash provided by operating activities was JPY 23,434 million against JPY 25,366 million a year ago. Purchase of property, plant and equipment were JPY 7,793 million against JPY 4,889 million a year ago. Purchase of intangible fixed assets was JPY 660 million against JPY 831 million a year ago. For the full year ending March 31, 2016, the company expects net sales of JPY 418,000 million, operating income of JPY 82,000 million, ordinary income of JPY 81,000 million, net income attributable to shareholders of the company of JPY 46,000 million or net income attributable to shareholders of the company per share of JPY 82.00.

Mitsubishi Tanabe Pharma Corporation, Q2 2016 Earnings Call, Oct 30, 2015

Mitsubishi Tanabe Pharma Corporation, Q2 2016 Earnings Call, Oct 30, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4508:JP ¥2,209.00 JPY -6.00

4508 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4508.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4508 Industry Range
Price/Earnings 33.3x
Price/Sales 2.9x
Price/Book 1.5x
Price/Cash Flow 24.7x
TEV/Sales 1.9x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact MITSUBISHI TANABE PHARMA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at